Orlistat Treatment of Crigler-Najjar Disease

• Status: Completed
• Trial end date: 2004-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to determine whether orlistat is effective in decreasing plasma unconjugated bilirubin levels in patients with Crigler-Najjar disease.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Medical Center Groningen
• Collaborators: De Najjar Stichting; Erasmus Medical Center
• Treatments: Orlistat

Criteria

Inclusion Criteria:

• patients with Crigler-Najjar disease above the age of 7 years

Exclusion Criteria:

• cholestasis, chronic malabsorption syndrome, pregnancy